A Panobinostat Presurgery

Recurrent Glioblastoma Clinical Trial

— CLBH589C  

Official title:

Phase II Study of Panobinostat (LBH589) for Recurrent Glioblastoma (GBM) Undergoing Planned Surgical Resection

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01115036
• Other study ID #: Pro00020612
• Status: Withdrawn
• Phase: Phase 2
• First received: April 30, 2010
• Last updated: June 17, 2013
• Start date: April 2010
• Est. completion date: April 2012

Study information

• Verified date: December 2011
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

In the current study, the investigators will evaluate intratumoral pharmacodynamic and pharmacokinetic data associated with the administration of the HDACI, Panobinostat, among recurrent GBM patients. In addition, this study will evaluate the safety and tolerability of this agent, as well as evidence of anti-tumor activity in the patient population.

Description:

This study will enroll a maximum of 24 subjects with recurrent GBM who are scheduled for planned debulking craniotomy.

After screening and enrollment on the study, subjects will receive 20mg panobinostat 3 times a week for one week prior to surgery. Within 2-6 weeks of resection, subjects will resume panobinostat at 20mg panobinostat 3 times per week.

The primary endpoint will be 6-month progression-free survival. Each cycle of therapy will be 28 days. All subjects will be assessed after every other cycle of therapy. Subjects will remain on study therapy for at least one year unless they develop progressive disease, unacceptable toxicity, non-compliance with study procedures or withdraw consent. Patients may continue treatment with oral panobinostat until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2012
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient age is = 18 years

• Histologically-confirmed grade 4 malignant glioma patients;

• Candidate for surgical resection of tumor;

• No more than 3 prior episodes of progressive disease;

• An interval of at least 4 weeks between prior surgical resection or two weeks from stereotactic biopsy;

• An interval of at least 12 weeks from the end of prior radiotherapy unless there is a new area of enhancement consistent with recurrent tumor outside of the radiation field, or there are progressive changes on MRI on at least two consecutive MRI scans at least four weeks apart, or there is biopsy-proven tumor progression;

• An interval of at least 4 weeks from prior chemotherapy (6 weeks for nitrosoureas) or investigational agent, unless the patient has recovered from all anticipated toxicities associated with that therapy;

• Karnofsky * 70%;

• Hemoglobin = 9 g/dL, ANC > 1,500 cells/*l, platelets > 150,000 cells/*l ;

• Serum creatinine < 1.5 mg/dl or 24-hour creatinine clearance = 50 ml/min, serum SGOT and bilirubin < 1.5 times upper limit of normal; total serum calcium (corrected for serum albumin) or ionized calcium = LLN; serum potassium = LLN; serum sodium = LLN; serum albumin = LLN or 3g/dl;

• Clinically euthyroid (Note: Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism);

• Baseline MUGA or ECHO must demonstrate LVEF = the lower limit of the institutional normal;

• Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed;

Exclusion Criteria:

• Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

• Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment;

• Use of CYP-3A inducing anti-epileptics (phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbitol, primidone);

• Pregnancy or breast feeding;

• Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids;

• Active infection requiring intravenous antibiotics;

• Prior bevacizumab within 6 weeks of study enrollment;

• Therapeutic anti-coagulation with warfarin, aspirin, non-steroidal anti-inflammatory drugs or clopidogrel;

• Impaired cardiac function including any one of the following:

• Complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (<50 beats per minute), QTcF > 450 msec on screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular block);

• Presence of atrial fibrillation (ventricular heart rate >100 bpm);

• Previous history angina pectoris or acute MI within 6 months;

• Congestive heart failure (New York Heart Association functional classification III-IV) or baseline MUGA/Echo shows LVEF < 45%;

• Uncontrolled hypertension;

• Concomitant use of drugs with a risk of causing Torsades de pointes (See Table 14-1);

• Patients with unresolved diarrhea = grade 2;

• Patients with = grade 2 peripheral neuropathy;

• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or small bowel resection)

• Other concurrent severe and/or uncontrolled medical conditions;

• Concomitant use of any anti-cancer therapy or radiation therapy;

• Patients with a history of another primary malignancy within 5 years other than curatively treated carcinoma in situ of the cervix, or basal or squamous cell carcinoma of the skin;

• Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required;

• Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.

• Women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of oral panobinostat;

• Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioblastoma
• Recurrent Glioblastoma

Intervention

Drug:
• panobinostat
Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	Novartis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anti-tumor Activity as Measured by Percentage of Patients Who Remain Progression-free after Six Months	The primary objective will be to determine the anti-tumor activity of panobinostat among recurrent GBM patients as measured by the percentage of patients who remain progression-free after 6 months of therapy (PFS-6)	18 months	No
Secondary	Safety Evaluation of Panobinostat	A secondary objective is to further evaluate the safety of panobinostat in recurrent GBM patients	24 months	Yes
Secondary	Evaluation of Intratumoral Pharmacokinetics and Pharmacodynamics of Panobinostat	A secondary objective is to evaluate the intratumoral pharmacokinetics and pharmacodynamics of panobinostat among recurrent GBM patients scheduled for surgical debulking	24 months	No
Secondary	Evaluation of Systemic Pharmacokinetics	A secondary objective is to evaluate the systemic pharmacokinetics of panobinostat among recurrent GBM patients.	24 months	No